Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
Spectrum of nontraumatic myelopathies in Ethiopian patients: hospital-based retrospective study.
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
TGFβ Signaling Regulates the Timing of CNS Myelination by Modulating Oligodendrocyte Progenitor Cell Cycle Exit through SMAD3/4/FoxO1/Sp1.
Mechanism-based CNS Disease Modeling: Applications in Neurology and Psychiatry Drug Research & Development
PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis.
New Drugs Online report for idebenone
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor.
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
Safety Study of Interferon Beta-1a for Acute Stroke
Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses.
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.
Keystone Symposium: Advances in the Knowledge and Treatment of Autoimmunity

Pages